Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma

N/ACompletedNCT01982097

Bayer61 enrolled

Overview

This local, prospective, multicenter, non-interventional study documents observational data on patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy. It's planned to better understand the impact of cytoreductive nephrectomy on Nexavar efficacy and possibly to define patients who get the most benefit from Nexavar before cytoreductive nephrectomy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Carcinoma, Renal Cell

Interventions

Sorafenib (Nexavar, BAY 43-9006)DRUG

The patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy meeting the criteria of inclusion.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * \- Male and female patients ≥ 18 years old * Patients with untreated metastatic RCC in whom a decision on neoadjuvant treatment with Nexavar before cytoreductive nephrectomy and in case of clinical feasibility resumption of treatment with Nexavar after nephrectomy has been made at the time of study enrollment * Life expectancy of at least 16 weeks * Patients should have signed informed consent form Exclusion Criteria: * Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, or in situ cervical cancer. * All contra-indications according to the Russian marketing authorization: * Hypersensitivity to sorafenib or to any of the excipients. * Pregnancy and breast-feeding. * Age less than 18 years.

Locations (1)

Unnamed facility

Multiple Locations, Russia

Outcomes

Primary Outcomes

Maximum percent reduction (based on the minimum post baseline value) in the longest diameter of the primary tumor in response to neoadjuvant Nexavar treatment.

Time frame: up to 2 years

Response rate of residual disease to Nexavar according to RECIST 1.1 with baseline after cytoreductive nephrectomy.

Time frame: up to 2 years

Secondary Outcomes

Response before cytoreductive nephrectomy according to RECIST 1.1.

Time frame: up to 2 years

Maximum percent reduction in the sum of longest diameters of target lesions according to RECIST 1.1 while on Nexavar treatment before cytoreductive nephrectomy

Time frame: up to 2 years

Maximum percent reduction in the sum of longest diameters of target lesions of residual disease after cytoreductive nephrectomy according to RECIST 1.1 while on Nexavar treatment with baseline after cytoreductive nephrectomy.

Time frame: up to 2 years

Number of participants with AEs, including intra- and postoperative complications, relation to Nexavar treatment, AEs treatment, AEs outcome.

Time frame: up to 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.